Drug plan cost increases have levelled in recent years due to the large number of high-volume medications becoming available in generic form and provincial drug reforms driving down the price of generic drugs. At the same time, some insurance carriers have automatically implemented mandatory generic substitution policies on the majority of their plans (giving plan sponsors the option to opt out if they choose). While generic substitution can help control drug plan costs, it does not always result in therapeutic equivalence in individual patients, and could lead to decreased efficacy and/or increased safety concerns.

This Drug Plan Substitutions Forum took place on February 8th, at the Royal York Hotel in Toronto. Download the PDF to read the conference coverage.






What Private Drug Plan Managers should know about Biosimilars entering Canada’s Healthcare Market



In Pursuit of Drug Plan Cost Savings–But at What Cost?

ADHD and Its Impact by Dr. Kenny Handelman